Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.73. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | VTIP | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | — |
52-Week High | $185.50 | $50.75 |
52-Week Low | $123.10 | $49.39 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
VTIP trades at $49.75 with minimal daily movement (+0.04%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The ETF focuses on short-term inflation-protected securities, offering minimal interest-rate sensitivity. Recent institutional activity includes 55 North Private Wealth increasing its position by 12.2% in Q2 2026.
Outlook remains cautious given bearish technical signals and persistent inflation concerns. The fund provides inflation hedging with reduced rate risk, but limited growth potential and competitive TIPS alternatives present challenges. Investors seeking short-duration inflation protection may find value, though overall market sentiment suggests tempered expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
